Generic Name: apomorphine hydrochloride
Brand Name: Kynmobi
Manufacturer: Sunovion Pharmaceuticals Canada Inc.
Therapeutic Area: Parkinson’s Disease
Indications: Parkinson’s Disease
Manufacturer Requested Reimbursement Criteria1: Kynmobi (apomorphine hydrochloride) sublingual film is anon-ergoline dopamine agonist indicated for the acute, intermittent treatment of hypomobility, OFF episodes associated with Parkinson’s disease including end-of-dose wearing OFF (including early morning OFF), partial/delayed/No-ON and unpredictable OFF.
Submission Type: Initial
Project Status: Withdrawn
Companion Diagnostics: No
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient input posted||January 25, 2019|
|Patient group input closed||March 18, 2019|
- Patient input submission received from the David Phinney Foundation for Parkinson's, Parkinson Association of Alberta, Parkinson Canada, Parkinson Society BC and The Michael J. Fox Foundation for Parkinson's Research
|Patient input summary sent for review to patient input groups||March 27, 2019|
|Patient group comments on input summary closed||April 02, 2019|
- Patient input summary feedback received
|Submission received||February 25, 2019|
|Submission accepted||March 11, 2019|
|Review initiated||March 12, 2019|
|Draft CADTH review report(s) sent to sponsor||May 27, 2019|
|Comments from sponsor on draft CADTH review report(s) received||June 05, 2019|
|Redaction requests from sponsor on draft CADTH review report(s) received||June 12, 2019|
- Voluntarily withdrawn by the manufacturer on 2019-Jun-19